SCHEMBL2642040

SCHEMBL2642040

OCc1ccccc1Sc1cnc2sc(Nc3ncnc4ccccc34)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
ABCG2 Q9UNQ0 6/20 0.38
HTT P42858 3/20 0.37
GLA P06280 1/20 0.37
EGFR P00533 7/20 0.37
DAPK3 O43293 1/20 0.37
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
ERBB2 P04626 1/20 0.37
PIM1 P11309 1/20 0.37
PRKACA P17612 1/20 0.37
LTK P29376 1/20 0.37
MAPK8 P45983 1/20 0.37
CSNK1A1 P48729 1/20 0.37
RPS6KA3 P51812 1/20 0.37
LIMK1 P53667 1/20 0.37
MAP2K1 Q02750 1/20 0.37
ACVR1 Q04771 1/20 0.37
TYRO3 Q06418 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642215 0.85 NSD2 (0.39) KMT2AMEN1ABCG2HTTGLA
SCHEMBL2642043 0.84 GCK (0.40) KMT2AMEN1ABCG2HTTGLA
SCHEMBL2646673 0.84 ABCG2 (0.38) KMT2AMEN1ABCG2HTTGLA
SCHEMBL2646676 0.83 EGFR (0.37) KMT2AABCG2HTTGLAEGFR
SCHEMBL2642645 0.80 ABCG2 (0.38) ABCG2HTTGLAEGFRDAPK3
SCHEMBL2642160 0.78 MET (0.39) KMT2AMEN1ABCG2HTTGLA
SCHEMBL2646674 0.77 GCK (0.39) KMT2AMEN1EGFRDYRK1AAURKB
SCHEMBL2642798 0.71 GCK (0.42) EGFRNPC1POLBSMN1; SMN2
SCHEMBL2642649 0.69 GCK (0.42) ABCG2EGFRDYRK1ANPC1POLB
SCHEMBL2660952 0.69 PKM (0.40) HTTEGFRNPC1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US claimed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US claimed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP claimed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK KMT2A 1505/4885MEN1 3505/4885ABCG2 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.